BALAXI PHARMACEUTICALS LIMITED Share Price & Company Info
- Market cap
- ₹106 Cras reported by NSE
- 52-week high
- ₹43.8504-NOV-2025
- 52-week low
- ₹15.2027-MAR-2026
- P/E (NSE)
- 43.61
- Face value
- ₹2.00
- Shares issued
- 5,52,07,500
- Volume
- 16,771₹0.04 Cr traded
- Delivery
- 92.59%of traded quantity
- Price band
- 20%₹15.77 – ₹23.65 on 2026-11-02
- Annual volatility
- 54.26%NSE, from daily returns
- Series
- EQrolling settlement
- ISIN
- INE618N01022
- Listed on NSE
- 30-Nov-2015
About BALAXI PHARMACEUTICALS LIMITED
BALAXI PHARMACEUTICALS LIMITED is listed on the National Stock Exchange of India under the symbol BALAXI in the EQ series. NSE classifies it under the basic industry Pharmaceuticals, part of the Healthcare sector. Its shares were listed on NSE on 30-Nov-2015. Each share has a face value of ₹2.00.
In the end-of-day data for 16 November 2026 the stock closed at ₹22.06, down 5.89% on the day. NSE puts the company's market capitalisation at about ₹106 crore, which puts it among the smallest listed companies in India. Over the past 52 weeks it has traded between ₹15.20 and ₹43.85, so the last price is 45.1% above the low and 49.7% below the high.
16,771 shares changed hands that day, and 92.59% of them were taken as delivery rather than squared off intraday. A high delivery share means most of the day's buyers chose to hold the shares; a low one usually means the volume was mostly short-term trading.
EQ is the normal equity series: shares settle on the usual T+1 cycle and intraday trading is allowed.
NSE currently lists a regulatory note for this stock: “Less than 100 unique PAN traded in prev. 30 days | High low price var. was greater than 150% in prev. 12 mths”. Notes like these come from the exchange's surveillance and disclosure checks and can mean higher margins, trade-for-trade settlement or limits on trading. Check the NSE quote page for the current position before trading.
NSE puts the stock's annualised volatility at 54.26%. That is well above the level of large, established companies, so double-digit swings within a month are common.
Because the share trades below ₹30, it also appears in our list of penny stocks under ₹30, which explains the extra risks that come with low-priced shares.
BALAXI PHARMACEUTICALS LIMITED quarterly results
In the quarter ended June 2026 (un-audited), BALAXI PHARMACEUTICALS LIMITED reported total income of ₹16.50 crore and a net loss of ₹1.25 crore, or ₹-0.23 per share.
Compared with the previous quarter (March 2026), income fell 30.1%.
BALAXI PHARMACEUTICALS LIMITED was profitable in 3 of the 4 quarters shown below. Figures are as filed with NSE, in ₹ crore.
| Quarter ended | Total income | Profit before tax | Net profit | EPS | Status |
|---|---|---|---|---|---|
| June 2026 | 16.50 | -1.12 | -1.25 | -0.23 | Un-Audited |
| March 2026 | 23.61 | 0.42 | 0.16 | 0.03 | Audited |
| December 2025 | 26.22 | 2.12 | 1.53 | 0.28 | Un-Audited |
| September 2025 | 23.52 | 4.24 | 3.26 | 0.59 | Un-Audited |
BALAXI PHARMACEUTICALS LIMITED shareholding pattern
At the end of September 2026, promoters and the promoter group held 65.99% of BALAXI PHARMACEUTICALS LIMITED, with the public holding 34.01%. The promoter stake has not changed across the 8 quarterly filings shown, from December 2024 to September 2026.
| Quarter ended | Promoter & Promoter Group (%) | Public (%) |
|---|---|---|
| September 2026 | 65.99 | 34.01 |
| June 2026 | 65.99 | 34.01 |
| March 2026 | 65.99 | 34.01 |
| December 2025 | 65.99 | 34.01 |
| September 2025 | 65.99 | 34.01 |
| June 2025 | 65.99 | 34.01 |
| March 2025 | 65.99 | 34.01 |
| December 2024 | 65.99 | 34.01 |
BALAXI PHARMACEUTICALS LIMITED share price performance
Over the past year the BALAXI PHARMACEUTICALS LIMITED share price has lost 53.46%, against a fall of 10.92% for the NIFTY 50, so it has underperformed that index by 42.54 percentage points.
Across the 7 periods in the table, the stock did not beat the NIFTY 50 in any of them. Past returns describe what happened; they do not predict what comes next.
| Period | BALAXI | NIFTY 50 |
|---|---|---|
| 1 month | -14.00% | +1.91% |
| 3 months | -20.07% | -5.20% |
| 6 months | -26.44% | -3.94% |
| 1 year | -53.46% | -10.92% |
| 2 years | -78.23% | -5.29% |
| 3 years | -76.24% | +20.44% |
| 5 years | -82.44% | +30.45% |
BALAXI PHARMACEUTICALS LIMITED vs industry peers
NSE compares BALAXI PHARMACEUTICALS LIMITED with 6 other listed companies in Pharmaceuticals. By market capitalisation it ranks 4 of 7.
Its P/E of 43.61 compares with a median of 22.80 for the other companies in the group: the market is paying considerably more for each rupee of its recent earnings.
| Company | Market cap | Price (₹) | P/E | Promoter % | Qtr income | Qtr net profit |
|---|---|---|---|---|---|---|
| SOTAC | 123 | 111.65 | 21.39 | 0.00 | — | — |
| KREBSBIO | 122 | 56.50 | — | 72.74 | 7.14 | -2.48 |
| MAKERSL | 115 | 195.50 | — | 0.00 | — | — |
| BALAXI | 108 | 19.59 | 43.61 | 65.99 | 16.50 | -1.25 |
| ALPA | 107 | 50.80 | 24.21 | 57.19 | 29.76 | 1.04 |
| VAISHALI | 87.61 | 6.49 | 19.56 | 31.61 | 23.47 | 1.49 |
| VILINBIO | 79.38 | 52.05 | 41.15 | 56.65 | — | — |
BALAXI PHARMACEUTICALS LIMITED announcements, board meetings and corporate actions
Latest announcements
The most recent filings BALAXI PHARMACEUTICALS LIMITED has made with NSE, newest first:
- 07-Oct-2026 · Certificate under SEBI (Depositories and Participants) Regulations, 2018: BALAXI PHARMACEUTICALS LIMITED has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 (PDF)
- 07-Oct-2026 · Updates: BALAXI PHARMACEUTICALS LIMITED has informed the Exchange regarding ''RTA Report for Re-lodgement of Transfer Requests of Physical Shares for the period ended September 2026." (PDF)
- 06-Oct-2026 · Copy of Newspaper Publication: BALAXI PHARMACEUTICALS LIMITED has informed the Exchange about Copy of Newspaper Publication (PDF)
- 27-Sep-2026 · Trading Window: BALAXI PHARMACEUTICALS LIMITED has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 (PDF)
- 07-Sep-2026 · Updates: BALAXI PHARMACEUTICALS LIMITED has informed the Exchange regarding '''RTA Report for Re-lodgement of Transfer Requests of Physical Shares for the period ended August 2026 .'. (PDF)
- 31-Aug-2026 · General Updates: Balaxi Pharmaceuticals Limited has informed the Exchange about the receipt of WHO-GMP Certification for Company's Pharmaceutical Formulation Manufacturing Facility. (PDF)
- 24-Aug-2026 · Change in Director(s): BALAXI PHARMACEUTICALS LIMITED has informed the Exchange regarding Change in Director(s) of the company. (PDF)
- 24-Aug-2026 · Shareholders meeting: BALAXI PHARMACEUTICALS LIMITED has submitted the Exchange a copy Srutinizers Report of Annual General Meeting held on 24th August, 2026. Further, the company has informed the Exchange regarding Voting Results. (PDF)
Board meetings
- 12-Nov-2026 · Financial Results/Other business matters: To consider and approve the Unaudited Standalone and Consolidated financial results of the Company for the second quarter and half year ended 30th September, 2026 of the Financial Year 2026-27, and other business matters.
- 05-Aug-2026 · Financial Results/Other business matters: To consider and approve the unaudited standalone and consolidated financial results of the Company for the first quarter ended 30th June, 2026 of the Financial Year 2026-27, and other business matters.
- 28-May-2026 · Financial Results/Other business matters: To consider and approve the audited financial results (Standalone and Consolidated) for the fourth quarter and financial year ended March 31, 2026 and other business matters
- 28-Jan-2026 · Financial Results/Other business matters: To consider and approve the financial results for the period ended December 31, 2025 and other business matters
- 11-Nov-2025 · Financial Results/Other business matters: To consider and approve the financial results for the period ended September 30, 2025 and other business matters
Corporate actions
The corporate actions on record include 1 dividend, 1 share split. The ex-date is the first day the shares trade without the entitlement.
- Face Value Split (Sub-Division) - From Rs 10/- Per Share To Rs 2/- Per Share · ex-date 30-May-2024 · record date 30-May-2024
- Annual General Meeting/Dividend - Rs 0.50 Per Share · ex-date 01-Jul-2022 · record date 04-Jul-2022
- Annual General Meeting · ex-date 21-Sep-2017 · book closure 24-Sep-2017 to 30-Sep-2017
- Annual General Meeting · ex-date 22-Sep-2016 · book closure 24-Sep-2016 to 30-Sep-2016
Risk notice: low-priced and small-company shares can be illiquid, volatile and subject to manipulation, and shareholders can lose their entire investment. This page is a factual summary, not a recommendation to buy or sell BALAXI PHARMACEUTICALS LIMITED.
Where to find BALAXI PHARMACEUTICALS LIMITED's financials
Direct downloads from NSE:
- Annual report 2025-26 (PDF, 5.60 MB)
- Annual report 2025-26 (PDF, 5.60 MB)
- Annual report 2024-25 (PDF)
- Annual report 2024-25 (PDF)
- Annual report 2023-24 (PDF)
- Annual report 2023-24 (PDF)
- Business responsibility and sustainability report (BRSR) 2025-26
- Business responsibility and sustainability report (BRSR) 2024-25
- Business responsibility and sustainability report (BRSR) 2023-24
For full financial statements, shareholding detail and every company announcement, go to the source:
- NSE quote pageOfficial price, price band, surveillance status, shareholding pattern and corporate actions.
- Annual reports (NSE)Search “BALAXI” to download BALAXI PHARMACEUTICALS LIMITED's annual reports as filed with the exchange.
- Announcements and results (NSE)Search “BALAXI” for quarterly results, board meetings and other company filings.
- ScreenerTen years of profit and loss, balance sheet, cash flow and key ratios.
- TradingView chartInteractive price chart with technical indicators.
- Google FinanceQuick price overview and recent news coverage.
- Yahoo FinanceHistorical prices you can download, plus summary statistics.
Other Pharmaceuticals stocks on MCX Trends
- Syncom Formulations (India) Limited (SYNCOMF · ₹21.19)
- Anlon Healthcare Limited (AHCL · ₹25.77)
- Sigachi Industries Limited (SIGACHI · ₹28.16)
- Vineet Laboratories Limited (VINEETLAB · ₹37.52)
- Ambalal Sarabhai Enterprises Limited (AMBALALSA · ₹38.62)
- Medico Remedies Limited (MEDICO · ₹18.31)
- Nectar Lifesciences Limited (NECLIFE · ₹10.31)
- Biofil Chemicals & Pharmaceuticals Limited (BIOFILCHEM · ₹30.67)
Frequently asked questions
What is the BALAXI PHARMACEUTICALS LIMITED share price?
BALAXI PHARMACEUTICALS LIMITED (NSE: BALAXI) closed at ₹22.06 in the end-of-day data for 16 November 2026. For a live price, use the NSE quote page or your broker, because this page is updated from end-of-day files.
Which sector does BALAXI PHARMACEUTICALS LIMITED belong to?
NSE classifies BALAXI PHARMACEUTICALS LIMITED under Pharmaceuticals, in the Healthcare sector.
What is the 52-week high and low of BALAXI?
The 52-week high is ₹43.85 (04-NOV-2025) and the 52-week low is ₹15.20 (27-MAR-2026), according to NSE.
Is BALAXI PHARMACEUTICALS LIMITED a penny stock?
At ₹22.06 the share trades below ₹30, so it appears on our list of penny stocks under ₹30. A low share price on its own says nothing about whether a company is cheap or expensive; market capitalisation, debt, profits and exchange surveillance status matter far more.
What is the promoter holding in BALAXI PHARMACEUTICALS LIMITED?
Promoters and the promoter group held 65.99% of BALAXI PHARMACEUTICALS LIMITED at the end of September 2026, according to the shareholding pattern filed with NSE.
What were BALAXI PHARMACEUTICALS LIMITED's latest quarterly results?
For the quarter ended June 2026, BALAXI PHARMACEUTICALS LIMITED reported total income of ₹16.50 crore and a net loss of ₹1.25 crore (EPS ₹-0.23).
Where can I find BALAXI PHARMACEUTICALS LIMITED's annual report and financial results?
Annual reports, quarterly results and other filings are published on the NSE corporate filings pages (search for BALAXI). Screener also lays out several years of financial statements in one place. Links to all of these are above.